Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi

We conducted a phase II study to assess activity and safety profile of bendamustine and rituximab in elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) who were prospectively defined as frail using a simplified version of the Comprehensive Geriatric Assessment (CGA). Patients had...

Descripción completa

Detalles Bibliográficos
Autores principales: Storti, Sergio, Spina, Michele, Pesce, Emanuela Anna, Salvi, Flavia, Merli, Michele, Ruffini, Alessia, Cabras, Giuseppina, Chiappella, Annalisa, Angelucci, Emanuele, Fabbri, Alberto, Liberati, Anna Marina, Tani, Monica, Musuraca, Gerardo, Molinari, Annalia, Petrilli, Maria Pia, Palladino, Carmela, Ciancia, Rosanna, Ferrario, Andrea, Gasbarrino, Cristiana, Monaco, Federico, Fraticelli, Vincenzo, De Vellis, Annalisa, Merli, Francesco, Luminari, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068040/
https://www.ncbi.nlm.nih.gov/pubmed/29748444
http://dx.doi.org/10.3324/haematol.2017.186569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068040/
https://www.ncbi.nlm.nih.gov/pubmed/29748444
http://dx.doi.org/10.3324/haematol.2017.186569

Ejemplares similares